Ivo Abraham, PhD, RN

Professor of Practice

Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan).  He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.

For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.  

More recently, frustrated by the abundance of evidence but clinicians’ persistent low adoption of evidence-based guidelines, he and his colleagues started examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.

He has (co-)authored 260+ articles and 60+ chapters, and has (co-)edited 29 books, monographs, and journal issues. Since 1984, his research has been funded by federal funding agencies, foundations, and corporations.   He has served as appointed ad hoc reviewer for the NIH, the NIMH, and the AHRQ. He currently serves as an expert adviser to the Innovative Medicines Initiative, a joint 2 billion euro undertaking of the European Union and the biopharmaceutical industry to stimulate innovation in human therapeutics.

His educational and scientific honors and awards include an Invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University.

View UA Profile

Education & Post Graduate Training: 

BS, Nursing, Katholieke Hogeschool Leuven (Leuven, Belgium)
MS, Psychiatric-Mental Health Nursing, University of Michigan
PhD, Clinical Research, University of Michigan 

Select Publications


Ludwig H, Gascón P, Bokemeyer C, et al. "Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study." Support Care Cancer. 2019;27(6):2301-2312. PMID: 30343410
Tahaineh L, Wazaify M, Alomoush F, Nasser SA, AlRawashdh N, Abraham I. "Physicians' perceptions, expectations, and experiences of clinical pharmacists in Jordan-2017." Int J Clin Pharm. 2019;41(5):1193-1201. PMID: 31377967
Almulhim ASaleh, Fallatah S, Abraham I. "Comparing incomparables with the wrong analytics: Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis." Thromb Res. 2019;178:110-111. PMID: 31005666
Barqawi YK, Borrego ME, Roberts MH, Abraham I. "Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance." J Med Econ. 2019;22(11):1202-1209. PMID: 31452414
Louis R, Pilette C, Michel O, et al. "Variability in total serum IgE over 1 year in severe asthmatics." Allergy Asthma Clin Immunol. 2019;15:20. PMCID: PMC6441212  PMID: 30976287
Ambade PNemdas, Katragadda C, Sun D, J Bootman L, Abraham I. "Why health policies should be transnational: A case for East Asia Pacific countries." Int J Risk Saf Med. 2019;30(2):101-125. PMID: 31282430
Garcia A, Frahm C, Jeter JM, et al. "Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without or Mutations." J Adv Pract Oncol. 2019;10(5):428-439. PMCID: PMC7779569  PMID: 33457057
Almutairi AR, Alkhatib NS, Abraham I. "The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs-Reply." JAMA Dermatol. 2019;155(7):863. PMID: 31066865
Andritsos LA, Huang Y, Abraham I, et al. "Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization." Leuk. Res.. 2019;85:106215. PMID: 31470355
Van Gaal L, Hermans MP, Daci E, et al. "Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study." Diabetes Ther. 2019;10(3):965-979. PMCID: PMC6531546  PMID: 30919316